Safety and Efficacy of Prolonged Hydroxycarbamide Administration in Patients with Sickle Cell Disease in Northwestern Greece
Alexandros Makis, Frideriki Koutsouka, Nikolaos Chaliasos, Eleni Kapsali & Evangelos Briasoulis · Journal of Advances in Medicine and Medical Research · 2015
Hydroxycarbamide (HC) is a ribonucleotide reductase inhibitor which promotes fetal hemoglobin (HbF) induction and has proven efficacy in sickle cell disease (SCD) patients. Given its mechanism of action and prior reports of genotoxicity in animal models, concern exists regarding...
Open access
Research Article
10.9734/BJMMR/2015/17515